These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
129 related items for PubMed ID: 15821633
21. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. Pediatr Infect Dis J; 2009 Feb; 28(2):86-91. PubMed ID: 19116603 [Abstract] [Full Text] [Related]
22. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep; 2005 May 27; 54(RR-7):1-21. PubMed ID: 15917737 [Abstract] [Full Text] [Related]
23. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Pediatr Infect Dis J; 2009 Mar 27; 28(3):186-93. PubMed ID: 19209097 [Abstract] [Full Text] [Related]
24. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Pace D. Expert Rev Vaccines; 2009 May 27; 8(5):529-42. PubMed ID: 19397410 [Abstract] [Full Text] [Related]
25. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Can Commun Dis Rep; 2009 Apr 27; 35(ACS-3):1-40. PubMed ID: 19400026 [No Abstract] [Full Text] [Related]
26. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE, Active Bacterial Core Surveillance Team. Clin Infect Dis; 2008 Jan 01; 46(1):1-13. PubMed ID: 18171206 [Abstract] [Full Text] [Related]
27. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE, Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Pediatr Infect Dis J; 2011 Jun 01; 30(6):451-5. PubMed ID: 21206392 [Abstract] [Full Text] [Related]
29. Meningococcal conjugate vaccine uptake, measured by Michigan's immunization registry. Enger KS, Stokley S. J Adolesc Health; 2007 May 01; 40(5):398-404. PubMed ID: 17448396 [Abstract] [Full Text] [Related]
30. Quadrivalent meningococcal conjugate vaccines. Pace D, Pollard AJ, Messonier NE. Vaccine; 2009 Jun 24; 27 Suppl 2():B30-41. PubMed ID: 19477560 [Abstract] [Full Text] [Related]
31. Syncope after vaccination--United States, January 2005-July 2007. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep; 2008 May 02; 57(17):457-60. PubMed ID: 18451756 [Abstract] [Full Text] [Related]
32. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. Trotter CL, Ramsay ME. FEMS Microbiol Rev; 2007 Jan 02; 31(1):101-7. PubMed ID: 17168998 [Abstract] [Full Text] [Related]
33. Meningococcal conjugate vaccine in adolescents and children. Pichichero ME. Clin Pediatr (Phila); 2005 Jan 02; 44(6):479-89. PubMed ID: 16015394 [Abstract] [Full Text] [Related]
34. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep; 2006 Oct 20; 55(41):1120-4. PubMed ID: 17060898 [Abstract] [Full Text] [Related]
35. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Halperin SA, Langley JM, Smith B, Wunderli P, Kaufman L, Kimura A, Martin D. Vaccine; 2007 Jan 05; 25(3):450-7. PubMed ID: 17052819 [Abstract] [Full Text] [Related]
36. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. El Bashir H, Heath PT, Papa T, Ruggeberg JU, Johnson N, Sinha R, Balfour G, Booy R. Vaccine; 2006 Mar 24; 24(14):2544-9. PubMed ID: 16417952 [Abstract] [Full Text] [Related]
37. Meningococcal disease: risk for international travellers and vaccine strategies. Wilder-Smith A. Travel Med Infect Dis; 2008 Jul 24; 6(4):182-6. PubMed ID: 18571105 [Abstract] [Full Text] [Related]
38. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. Pichichero M, Papa T, Blatter M, Mitchell D, Kratz R, Sneed J, Bassily E, Casey J, Gilmet G. Pediatr Infect Dis J; 2006 Nov 24; 25(11):995-1000. PubMed ID: 17072120 [Abstract] [Full Text] [Related]
39. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. America Academy of Pediatrics Commitee on Infectious Diseases. Pediatrics; 2006 Mar 24; 117(3):965-78. PubMed ID: 16382131 [Abstract] [Full Text] [Related]